Wolverine Asset Management LLC Clovis Oncology, Inc. Transaction History

Wolverine Asset Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$1.05 - $2.85 $42,541 - $115,470	40,516 New	40,516 $48,000
Q2 2020 Aug 13, 2020	SELL	$5.69 - $9.69 $1.35 Million - $2.29 Million	-236,500 Reduced 96.64%	8,213 $55,000
Q1 2020 May 13, 2020	BUY	$3.77 - $11.0 $904,230 - $2.64 Million	239,849 Added 4931.11%	244,713 $1.56 Million
Q4 2018 Feb 14, 2019	BUY	$11.63 - $32.67 $40,705 - $114,345	3,500 Added 256.6%	4,864 $87,000
Q3 2018 Nov 14, 2018	SELL	$29.37 - $49.48 $38,063 - $64,126	-1,296 Reduced 48.72%	1,364 $40,000
Q2 2018 Aug 14, 2018	BUY	$42.06 - $62.4 $34,068 - $50,544	810 Added 43.78%	2,660 $120,000
Q1 2018 May 15, 2018	SELL	$50.12 - $67.72 $25,711 - $34,740	-513 Reduced 21.71%	1,850 $97,000
Q4 2017 Feb 14, 2018	SELL	$57.69 - $84.58 $309,910 - $454,363	-5,372 Reduced 69.45%	2,363 $160,000
Q3 2017 Nov 14, 2017	SELL	$67.17 - $84.81 $125,272 - $158,170	-1,865 Reduced 19.43%	7,735 $637,000
Q2 2017 Aug 14, 2017	BUY	N/A	9,600	9,600 $898,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Wolverine Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Asset Management LLC with notifications on news.